nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A1—kidney cancer	0.42	1	CbGaD
Dexmedetomidine—CYP1A1—Erlotinib—kidney cancer	0.052	0.197	CbGbCtD
Dexmedetomidine—CYP2D6—Temsirolimus—kidney cancer	0.051	0.193	CbGbCtD
Dexmedetomidine—CYP1A2—Pazopanib—kidney cancer	0.0325	0.123	CbGbCtD
Dexmedetomidine—CYP2D6—Pazopanib—kidney cancer	0.0268	0.102	CbGbCtD
Dexmedetomidine—CYP1A2—Erlotinib—kidney cancer	0.0232	0.088	CbGbCtD
Dexmedetomidine—CYP2D6—Erlotinib—kidney cancer	0.0191	0.0725	CbGbCtD
Dexmedetomidine—CYP1A2—Sorafenib—kidney cancer	0.0189	0.0715	CbGbCtD
Dexmedetomidine—CYP2D6—Sorafenib—kidney cancer	0.0156	0.0589	CbGbCtD
Dexmedetomidine—CYP2D6—Vinblastine—kidney cancer	0.0154	0.0582	CbGbCtD
Dexmedetomidine—CYP2D6—Doxorubicin—kidney cancer	0.00944	0.0358	CbGbCtD
Dexmedetomidine—CYP1A2—urine—kidney cancer	0.002	0.124	CbGeAlD
Dexmedetomidine—CYP2E1—urine—kidney cancer	0.0018	0.111	CbGeAlD
Dexmedetomidine—CYP2D6—urine—kidney cancer	0.00142	0.088	CbGeAlD
Dexmedetomidine—ADRA1B—renal system—kidney cancer	0.00105	0.0651	CbGeAlD
Dexmedetomidine—ADRA1B—kidney—kidney cancer	0.00102	0.0629	CbGeAlD
Dexmedetomidine—ADRA2C—nephron tubule—kidney cancer	0.00062	0.0383	CbGeAlD
Dexmedetomidine—SLC6A2—gonad—kidney cancer	0.000571	0.0353	CbGeAlD
Dexmedetomidine—ADRA2C—renal system—kidney cancer	0.000564	0.0348	CbGeAlD
Dexmedetomidine—ADRA2C—kidney—kidney cancer	0.000545	0.0337	CbGeAlD
Dexmedetomidine—ADRA2C—cortex of kidney—kidney cancer	0.000531	0.0328	CbGeAlD
Dexmedetomidine—ADRA2C—cardiac atrium—kidney cancer	0.000505	0.0312	CbGeAlD
Dexmedetomidine—CYP1A2—renal system—kidney cancer	0.000489	0.0302	CbGeAlD
Dexmedetomidine—CYP2E1—nephron tubule—kidney cancer	0.000484	0.0299	CbGeAlD
Dexmedetomidine—CYP1A1—renal system—kidney cancer	0.000482	0.0298	CbGeAlD
Dexmedetomidine—CYP1A1—kidney—kidney cancer	0.000466	0.0288	CbGeAlD
Dexmedetomidine—CYP2E1—renal system—kidney cancer	0.00044	0.0272	CbGeAlD
Dexmedetomidine—CYP1A1—cardiac atrium—kidney cancer	0.000432	0.0267	CbGeAlD
Dexmedetomidine—CYP2E1—kidney—kidney cancer	0.000425	0.0263	CbGeAlD
Dexmedetomidine—ADRA2A—cortex of kidney—kidney cancer	0.000423	0.0262	CbGeAlD
Dexmedetomidine—CYP2E1—cortex of kidney—kidney cancer	0.000414	0.0256	CbGeAlD
Dexmedetomidine—ADRA2A—gonad—kidney cancer	0.000403	0.0249	CbGeAlD
Dexmedetomidine—ADRA2A—cardiac atrium—kidney cancer	0.000403	0.0249	CbGeAlD
Dexmedetomidine—CYP2D6—renal system—kidney cancer	0.000348	0.0215	CbGeAlD
Dexmedetomidine—CYP2D6—kidney—kidney cancer	0.000337	0.0208	CbGeAlD
Dexmedetomidine—Rash—Pazopanib—kidney cancer	0.000214	0.000821	CcSEcCtD
Dexmedetomidine—Nausea—Temsirolimus—kidney cancer	0.000214	0.000821	CcSEcCtD
Dexmedetomidine—Dermatitis—Pazopanib—kidney cancer	0.000214	0.00082	CcSEcCtD
Dexmedetomidine—Bronchospasm—Capecitabine—kidney cancer	0.000214	0.000819	CcSEcCtD
Dexmedetomidine—Agitation—Vincristine—kidney cancer	0.000213	0.000818	CcSEcCtD
Dexmedetomidine—Haemoglobin—Paclitaxel—kidney cancer	0.000213	0.000816	CcSEcCtD
Dexmedetomidine—Abdominal pain—Vinblastine—kidney cancer	0.000213	0.000816	CcSEcCtD
Dexmedetomidine—Headache—Pazopanib—kidney cancer	0.000213	0.000816	CcSEcCtD
Dexmedetomidine—Abdominal pain—Everolimus—kidney cancer	0.000212	0.000813	CcSEcCtD
Dexmedetomidine—Body temperature increased—Everolimus—kidney cancer	0.000212	0.000813	CcSEcCtD
Dexmedetomidine—Fluid retention—Doxorubicin—kidney cancer	0.000212	0.000812	CcSEcCtD
Dexmedetomidine—Haemorrhage—Paclitaxel—kidney cancer	0.000212	0.000812	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Erlotinib—kidney cancer	0.000212	0.000811	CcSEcCtD
Dexmedetomidine—Sweating increased—Capecitabine—kidney cancer	0.000212	0.000811	CcSEcCtD
Dexmedetomidine—Infection—Dactinomycin—kidney cancer	0.000211	0.000808	CcSEcCtD
Dexmedetomidine—Blood urea increased—Doxorubicin—kidney cancer	0.000211	0.000808	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Paclitaxel—kidney cancer	0.000209	0.0008	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Dactinomycin—kidney cancer	0.000208	0.000796	CcSEcCtD
Dexmedetomidine—Dyspnoea—Sorafenib—kidney cancer	0.000208	0.000796	CcSEcCtD
Dexmedetomidine—Abdominal pain—Erlotinib—kidney cancer	0.000205	0.000784	CcSEcCtD
Dexmedetomidine—Body temperature increased—Erlotinib—kidney cancer	0.000205	0.000784	CcSEcCtD
Dexmedetomidine—Visual impairment—Paclitaxel—kidney cancer	0.000204	0.000783	CcSEcCtD
Dexmedetomidine—Anaemia—Gemcitabine—kidney cancer	0.000204	0.00078	CcSEcCtD
Dexmedetomidine—Nausea—Pazopanib—kidney cancer	0.000202	0.000773	CcSEcCtD
Dexmedetomidine—Convulsion—Vincristine—kidney cancer	0.000201	0.000771	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000201	0.00077	CcSEcCtD
Dexmedetomidine—Hypertension—Vincristine—kidney cancer	0.0002	0.000768	CcSEcCtD
Dexmedetomidine—Dyspnoea—Sunitinib—kidney cancer	0.0002	0.000766	CcSEcCtD
Dexmedetomidine—Constipation—Sorafenib—kidney cancer	0.000199	0.000763	CcSEcCtD
Dexmedetomidine—Pain—Sorafenib—kidney cancer	0.000199	0.000763	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Doxorubicin—kidney cancer	0.000199	0.000761	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Paclitaxel—kidney cancer	0.000197	0.000754	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Capecitabine—kidney cancer	0.000196	0.000751	CcSEcCtD
Dexmedetomidine—Pneumonia—Capecitabine—kidney cancer	0.000195	0.000747	CcSEcCtD
Dexmedetomidine—Abnormal vision—Doxorubicin—kidney cancer	0.000195	0.000746	CcSEcCtD
Dexmedetomidine—Sepsis—Doxorubicin—kidney cancer	0.000194	0.000742	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000193	0.000741	CcSEcCtD
Dexmedetomidine—Angiopathy—Paclitaxel—kidney cancer	0.000192	0.000737	CcSEcCtD
Dexmedetomidine—Constipation—Sunitinib—kidney cancer	0.000192	0.000734	CcSEcCtD
Dexmedetomidine—Pain—Sunitinib—kidney cancer	0.000192	0.000734	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Paclitaxel—kidney cancer	0.000191	0.000732	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Capecitabine—kidney cancer	0.000191	0.000732	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Sorafenib—kidney cancer	0.00019	0.00073	CcSEcCtD
Dexmedetomidine—Hypertension—Gemcitabine—kidney cancer	0.00019	0.000729	CcSEcCtD
Dexmedetomidine—Chills—Paclitaxel—kidney cancer	0.00019	0.000729	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Capecitabine—kidney cancer	0.00019	0.000728	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Capecitabine—kidney cancer	0.00019	0.000728	CcSEcCtD
Dexmedetomidine—Arrhythmia—Paclitaxel—kidney cancer	0.000189	0.000725	CcSEcCtD
Dexmedetomidine—Infection—Vincristine—kidney cancer	0.000188	0.000722	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Capecitabine—kidney cancer	0.000188	0.000722	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Doxorubicin—kidney cancer	0.000186	0.000714	CcSEcCtD
Dexmedetomidine—Mental disorder—Paclitaxel—kidney cancer	0.000186	0.000711	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Vincristine—kidney cancer	0.000186	0.000711	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000185	0.00071	CcSEcCtD
Dexmedetomidine—Malnutrition—Paclitaxel—kidney cancer	0.000184	0.000707	CcSEcCtD
Dexmedetomidine—Diarrhoea—Vinblastine—kidney cancer	0.000184	0.000706	CcSEcCtD
Dexmedetomidine—Abdominal pain—Sorafenib—kidney cancer	0.000184	0.000705	CcSEcCtD
Dexmedetomidine—Body temperature increased—Sorafenib—kidney cancer	0.000184	0.000705	CcSEcCtD
Dexmedetomidine—Diarrhoea—Everolimus—kidney cancer	0.000184	0.000703	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Sunitinib—kidney cancer	0.000183	0.000702	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Vincristine—kidney cancer	0.000183	0.000702	CcSEcCtD
Dexmedetomidine—Pain—Dactinomycin—kidney cancer	0.000181	0.000695	CcSEcCtD
Dexmedetomidine—Infection—Gemcitabine—kidney cancer	0.000179	0.000685	CcSEcCtD
Dexmedetomidine—Dizziness—Vinblastine—kidney cancer	0.000178	0.000682	CcSEcCtD
Dexmedetomidine—Dizziness—Everolimus—kidney cancer	0.000177	0.00068	CcSEcCtD
Dexmedetomidine—Abdominal pain—Sunitinib—kidney cancer	0.000177	0.000679	CcSEcCtD
Dexmedetomidine—Body temperature increased—Sunitinib—kidney cancer	0.000177	0.000679	CcSEcCtD
Dexmedetomidine—Diarrhoea—Erlotinib—kidney cancer	0.000177	0.000679	CcSEcCtD
Dexmedetomidine—Hypotension—Vincristine—kidney cancer	0.000177	0.000679	CcSEcCtD
Dexmedetomidine—Bradycardia—Capecitabine—kidney cancer	0.000177	0.000678	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Gemcitabine—kidney cancer	0.000176	0.000675	CcSEcCtD
Dexmedetomidine—Renal failure acute—Doxorubicin—kidney cancer	0.000175	0.000673	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Dactinomycin—kidney cancer	0.000175	0.00067	CcSEcCtD
Dexmedetomidine—Haemoglobin—Capecitabine—kidney cancer	0.000175	0.00067	CcSEcCtD
Dexmedetomidine—Haemorrhage—Capecitabine—kidney cancer	0.000174	0.000666	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000174	0.000666	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000173	0.000665	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Capecitabine—kidney cancer	0.000171	0.000656	CcSEcCtD
Dexmedetomidine—Vomiting—Vinblastine—kidney cancer	0.000171	0.000656	CcSEcCtD
Dexmedetomidine—Dizziness—Erlotinib—kidney cancer	0.000171	0.000656	CcSEcCtD
Dexmedetomidine—Vomiting—Everolimus—kidney cancer	0.000171	0.000654	CcSEcCtD
Dexmedetomidine—Anaemia—Paclitaxel—kidney cancer	0.00017	0.000653	CcSEcCtD
Dexmedetomidine—Agitation—Paclitaxel—kidney cancer	0.000169	0.00065	CcSEcCtD
Dexmedetomidine—Rash—Everolimus—kidney cancer	0.000169	0.000648	CcSEcCtD
Dexmedetomidine—Dermatitis—Everolimus—kidney cancer	0.000169	0.000648	CcSEcCtD
Dexmedetomidine—Headache—Vinblastine—kidney cancer	0.000169	0.000647	CcSEcCtD
Dexmedetomidine—Headache—Everolimus—kidney cancer	0.000168	0.000644	CcSEcCtD
Dexmedetomidine—Hypotension—Gemcitabine—kidney cancer	0.000168	0.000644	CcSEcCtD
Dexmedetomidine—Abdominal pain—Dactinomycin—kidney cancer	0.000168	0.000643	CcSEcCtD
Dexmedetomidine—Body temperature increased—Dactinomycin—kidney cancer	0.000168	0.000643	CcSEcCtD
Dexmedetomidine—Visual impairment—Capecitabine—kidney cancer	0.000168	0.000642	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—kidney cancer	0.000166	0.000636	CcSEcCtD
Dexmedetomidine—Vomiting—Erlotinib—kidney cancer	0.000165	0.000631	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000164	0.000627	CcSEcCtD
Dexmedetomidine—Rash—Erlotinib—kidney cancer	0.000163	0.000625	CcSEcCtD
Dexmedetomidine—Dermatitis—Erlotinib—kidney cancer	0.000163	0.000625	CcSEcCtD
Dexmedetomidine—Headache—Erlotinib—kidney cancer	0.000162	0.000621	CcSEcCtD
Dexmedetomidine—Constipation—Vincristine—kidney cancer	0.000162	0.000621	CcSEcCtD
Dexmedetomidine—Pain—Vincristine—kidney cancer	0.000162	0.000621	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Capecitabine—kidney cancer	0.000161	0.000618	CcSEcCtD
Dexmedetomidine—Dyspnoea—Gemcitabine—kidney cancer	0.00016	0.000614	CcSEcCtD
Dexmedetomidine—Nausea—Vinblastine—kidney cancer	0.00016	0.000613	CcSEcCtD
Dexmedetomidine—Somnolence—Gemcitabine—kidney cancer	0.00016	0.000613	CcSEcCtD
Dexmedetomidine—Convulsion—Paclitaxel—kidney cancer	0.00016	0.000612	CcSEcCtD
Dexmedetomidine—Nausea—Everolimus—kidney cancer	0.000159	0.000611	CcSEcCtD
Dexmedetomidine—Diarrhoea—Sorafenib—kidney cancer	0.000159	0.000611	CcSEcCtD
Dexmedetomidine—Hypertension—Paclitaxel—kidney cancer	0.000159	0.00061	CcSEcCtD
Dexmedetomidine—Angiopathy—Capecitabine—kidney cancer	0.000158	0.000605	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Capecitabine—kidney cancer	0.000157	0.000601	CcSEcCtD
Dexmedetomidine—Anxiety—Paclitaxel—kidney cancer	0.000156	0.0006	CcSEcCtD
Dexmedetomidine—Chills—Capecitabine—kidney cancer	0.000156	0.000598	CcSEcCtD
Dexmedetomidine—Arrhythmia—Capecitabine—kidney cancer	0.000155	0.000595	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000155	0.000595	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Vincristine—kidney cancer	0.000155	0.000594	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—kidney cancer	0.000154	0.00059	CcSEcCtD
Dexmedetomidine—Dizziness—Sorafenib—kidney cancer	0.000154	0.00059	CcSEcCtD
Dexmedetomidine—Pain—Gemcitabine—kidney cancer	0.000154	0.000589	CcSEcCtD
Dexmedetomidine—Constipation—Gemcitabine—kidney cancer	0.000154	0.000589	CcSEcCtD
Dexmedetomidine—Nausea—Erlotinib—kidney cancer	0.000154	0.000589	CcSEcCtD
Dexmedetomidine—Dry mouth—Paclitaxel—kidney cancer	0.000154	0.000589	CcSEcCtD
Dexmedetomidine—Diarrhoea—Sunitinib—kidney cancer	0.000153	0.000588	CcSEcCtD
Dexmedetomidine—Mental disorder—Capecitabine—kidney cancer	0.000152	0.000584	CcSEcCtD
Dexmedetomidine—Confusional state—Paclitaxel—kidney cancer	0.000152	0.000582	CcSEcCtD
Dexmedetomidine—Malnutrition—Capecitabine—kidney cancer	0.000151	0.00058	CcSEcCtD
Dexmedetomidine—Abdominal pain—Vincristine—kidney cancer	0.00015	0.000574	CcSEcCtD
Dexmedetomidine—Body temperature increased—Vincristine—kidney cancer	0.00015	0.000574	CcSEcCtD
Dexmedetomidine—Infection—Paclitaxel—kidney cancer	0.00015	0.000573	CcSEcCtD
Dexmedetomidine—Dizziness—Sunitinib—kidney cancer	0.000148	0.000568	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Gemcitabine—kidney cancer	0.000148	0.000568	CcSEcCtD
Dexmedetomidine—Vomiting—Sorafenib—kidney cancer	0.000148	0.000567	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—kidney cancer	0.000147	0.000565	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Paclitaxel—kidney cancer	0.000147	0.000565	CcSEcCtD
Dexmedetomidine—Tachycardia—Paclitaxel—kidney cancer	0.000147	0.000563	CcSEcCtD
Dexmedetomidine—Rash—Sorafenib—kidney cancer	0.000147	0.000563	CcSEcCtD
Dexmedetomidine—Dermatitis—Sorafenib—kidney cancer	0.000147	0.000562	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000146	0.000559	CcSEcCtD
Dexmedetomidine—Headache—Sorafenib—kidney cancer	0.000146	0.000559	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000146	0.000558	CcSEcCtD
Dexmedetomidine—Diarrhoea—Dactinomycin—kidney cancer	0.000145	0.000556	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.000143	0.000548	CcSEcCtD
Dexmedetomidine—Vomiting—Sunitinib—kidney cancer	0.000142	0.000546	CcSEcCtD
Dexmedetomidine—Body temperature increased—Gemcitabine—kidney cancer	0.000142	0.000545	CcSEcCtD
Dexmedetomidine—Rash—Sunitinib—kidney cancer	0.000141	0.000541	CcSEcCtD
Dexmedetomidine—Dermatitis—Sunitinib—kidney cancer	0.000141	0.000541	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—kidney cancer	0.000141	0.00054	CcSEcCtD
Dexmedetomidine—Hypotension—Paclitaxel—kidney cancer	0.000141	0.000539	CcSEcCtD
Dexmedetomidine—Headache—Sunitinib—kidney cancer	0.00014	0.000538	CcSEcCtD
Dexmedetomidine—Anaemia—Capecitabine—kidney cancer	0.00014	0.000536	CcSEcCtD
Dexmedetomidine—Nausea—Sorafenib—kidney cancer	0.000138	0.00053	CcSEcCtD
Dexmedetomidine—Vomiting—Dactinomycin—kidney cancer	0.000135	0.000517	CcSEcCtD
Dexmedetomidine—Dyspnoea—Paclitaxel—kidney cancer	0.000134	0.000514	CcSEcCtD
Dexmedetomidine—Somnolence—Paclitaxel—kidney cancer	0.000134	0.000513	CcSEcCtD
Dexmedetomidine—Rash—Dactinomycin—kidney cancer	0.000134	0.000513	CcSEcCtD
Dexmedetomidine—Nausea—Sunitinib—kidney cancer	0.000133	0.00051	CcSEcCtD
Dexmedetomidine—Hypertension—Capecitabine—kidney cancer	0.000131	0.000501	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.00013	0.000498	CcSEcCtD
Dexmedetomidine—Diarrhoea—Vincristine—kidney cancer	0.00013	0.000497	CcSEcCtD
Dexmedetomidine—Constipation—Paclitaxel—kidney cancer	0.000129	0.000493	CcSEcCtD
Dexmedetomidine—Pain—Paclitaxel—kidney cancer	0.000129	0.000493	CcSEcCtD
Dexmedetomidine—Anxiety—Capecitabine—kidney cancer	0.000128	0.000492	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—kidney cancer	0.000126	0.000484	CcSEcCtD
Dexmedetomidine—Dry mouth—Capecitabine—kidney cancer	0.000126	0.000483	CcSEcCtD
Dexmedetomidine—Nausea—Dactinomycin—kidney cancer	0.000126	0.000483	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—kidney cancer	0.000126	0.000481	CcSEcCtD
Dexmedetomidine—Dizziness—Vincristine—kidney cancer	0.000125	0.00048	CcSEcCtD
Dexmedetomidine—Confusional state—Capecitabine—kidney cancer	0.000125	0.000477	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Paclitaxel—kidney cancer	0.000124	0.000475	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000123	0.000472	CcSEcCtD
Dexmedetomidine—Diarrhoea—Gemcitabine—kidney cancer	0.000123	0.000471	CcSEcCtD
Dexmedetomidine—Infection—Capecitabine—kidney cancer	0.000123	0.00047	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000122	0.000469	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—kidney cancer	0.000121	0.000465	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Capecitabine—kidney cancer	0.000121	0.000464	CcSEcCtD
Dexmedetomidine—Tachycardia—Capecitabine—kidney cancer	0.000121	0.000462	CcSEcCtD
Dexmedetomidine—Vomiting—Vincristine—kidney cancer	0.00012	0.000462	CcSEcCtD
Dexmedetomidine—Rash—Vincristine—kidney cancer	0.000119	0.000458	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Capecitabine—kidney cancer	0.000119	0.000458	CcSEcCtD
Dexmedetomidine—Dermatitis—Vincristine—kidney cancer	0.000119	0.000458	CcSEcCtD
Dexmedetomidine—Body temperature increased—Paclitaxel—kidney cancer	0.000119	0.000456	CcSEcCtD
Dexmedetomidine—Abdominal pain—Paclitaxel—kidney cancer	0.000119	0.000456	CcSEcCtD
Dexmedetomidine—Headache—Vincristine—kidney cancer	0.000119	0.000455	CcSEcCtD
Dexmedetomidine—Hypotension—Capecitabine—kidney cancer	0.000115	0.000442	CcSEcCtD
Dexmedetomidine—Vomiting—Gemcitabine—kidney cancer	0.000114	0.000438	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—kidney cancer	0.000114	0.000437	CcSEcCtD
Dexmedetomidine—Rash—Gemcitabine—kidney cancer	0.000113	0.000434	CcSEcCtD
Dexmedetomidine—Dermatitis—Gemcitabine—kidney cancer	0.000113	0.000434	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—kidney cancer	0.000113	0.000432	CcSEcCtD
Dexmedetomidine—Headache—Gemcitabine—kidney cancer	0.000113	0.000432	CcSEcCtD
Dexmedetomidine—Nausea—Vincristine—kidney cancer	0.000113	0.000431	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—kidney cancer	0.000112	0.00043	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—kidney cancer	0.00011	0.000423	CcSEcCtD
Dexmedetomidine—Dyspnoea—Capecitabine—kidney cancer	0.00011	0.000422	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—kidney cancer	0.000108	0.000414	CcSEcCtD
Dexmedetomidine—Nausea—Gemcitabine—kidney cancer	0.000107	0.000409	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000107	0.000409	CcSEcCtD
Dexmedetomidine—Pain—Capecitabine—kidney cancer	0.000106	0.000405	CcSEcCtD
Dexmedetomidine—Constipation—Capecitabine—kidney cancer	0.000106	0.000405	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—kidney cancer	0.000104	0.000399	CcSEcCtD
Dexmedetomidine—Diarrhoea—Paclitaxel—kidney cancer	0.000103	0.000395	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Capecitabine—kidney cancer	0.000102	0.00039	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—kidney cancer	0.000102	0.00039	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000101	0.000387	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000101	0.000387	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—kidney cancer	0.000101	0.000385	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—kidney cancer	0.0001	0.000384	CcSEcCtD
Dexmedetomidine—Dizziness—Paclitaxel—kidney cancer	9.95e-05	0.000381	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—kidney cancer	9.82e-05	0.000376	CcSEcCtD
Dexmedetomidine—Abdominal pain—Capecitabine—kidney cancer	9.76e-05	0.000374	CcSEcCtD
Dexmedetomidine—Body temperature increased—Capecitabine—kidney cancer	9.76e-05	0.000374	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—kidney cancer	9.76e-05	0.000374	CcSEcCtD
Dexmedetomidine—Vomiting—Paclitaxel—kidney cancer	9.57e-05	0.000367	CcSEcCtD
Dexmedetomidine—Rash—Paclitaxel—kidney cancer	9.49e-05	0.000364	CcSEcCtD
Dexmedetomidine—Dermatitis—Paclitaxel—kidney cancer	9.48e-05	0.000363	CcSEcCtD
Dexmedetomidine—Headache—Paclitaxel—kidney cancer	9.43e-05	0.000361	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—kidney cancer	9.02e-05	0.000346	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—kidney cancer	8.96e-05	0.000344	CcSEcCtD
Dexmedetomidine—Nausea—Paclitaxel—kidney cancer	8.94e-05	0.000343	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—kidney cancer	8.45e-05	0.000324	CcSEcCtD
Dexmedetomidine—Diarrhoea—Capecitabine—kidney cancer	8.45e-05	0.000324	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—kidney cancer	8.42e-05	0.000323	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—kidney cancer	8.28e-05	0.000317	CcSEcCtD
Dexmedetomidine—Dizziness—Capecitabine—kidney cancer	8.17e-05	0.000313	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—kidney cancer	8.12e-05	0.000311	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—kidney cancer	8.03e-05	0.000308	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—kidney cancer	7.91e-05	0.000303	CcSEcCtD
Dexmedetomidine—Vomiting—Capecitabine—kidney cancer	7.85e-05	0.000301	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—kidney cancer	7.8e-05	0.000299	CcSEcCtD
Dexmedetomidine—Rash—Capecitabine—kidney cancer	7.79e-05	0.000299	CcSEcCtD
Dexmedetomidine—Dermatitis—Capecitabine—kidney cancer	7.78e-05	0.000298	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—kidney cancer	7.77e-05	0.000298	CcSEcCtD
Dexmedetomidine—Headache—Capecitabine—kidney cancer	7.74e-05	0.000297	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—kidney cancer	7.7e-05	0.000295	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—kidney cancer	7.44e-05	0.000285	CcSEcCtD
Dexmedetomidine—Nausea—Capecitabine—kidney cancer	7.34e-05	0.000281	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—kidney cancer	7.1e-05	0.000272	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—kidney cancer	7.08e-05	0.000271	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—kidney cancer	6.87e-05	0.000263	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—kidney cancer	6.81e-05	0.000261	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—kidney cancer	6.81e-05	0.000261	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—kidney cancer	6.56e-05	0.000251	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—kidney cancer	6.51e-05	0.00025	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—kidney cancer	6.29e-05	0.000241	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—kidney cancer	6.29e-05	0.000241	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—kidney cancer	5.45e-05	0.000209	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—kidney cancer	5.26e-05	0.000202	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—kidney cancer	5.06e-05	0.000194	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—kidney cancer	5.02e-05	0.000192	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—kidney cancer	5.02e-05	0.000192	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—kidney cancer	4.99e-05	0.000191	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—kidney cancer	4.73e-05	0.000181	CcSEcCtD
Dexmedetomidine—ADRA2B—Hemostasis—PIK3CA—kidney cancer	9.52e-06	0.000242	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ITPR2—kidney cancer	9.47e-06	0.000241	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—POMC—kidney cancer	9.3e-06	0.000237	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.25e-06	0.000235	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—VEGFA—kidney cancer	9.25e-06	0.000235	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—kidney cancer	9.21e-06	0.000234	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF2—kidney cancer	9.21e-06	0.000234	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTP1—kidney cancer	9.19e-06	0.000234	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—RAF1—kidney cancer	9.18e-06	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN2B—kidney cancer	9.17e-06	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PAK1—kidney cancer	9.15e-06	0.000232	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JUNB—kidney cancer	9.15e-06	0.000232	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL2—kidney cancer	9.12e-06	0.000232	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—IL2—kidney cancer	9.07e-06	0.00023	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF2—kidney cancer	9.06e-06	0.00023	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN2B—kidney cancer	9.02e-06	0.000229	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF1R—kidney cancer	8.9e-06	0.000226	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—PIK3CA—kidney cancer	8.89e-06	0.000226	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF1R—kidney cancer	8.76e-06	0.000223	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—MAPK3—kidney cancer	8.75e-06	0.000222	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ABCB1—kidney cancer	8.7e-06	0.000221	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HIF1A—kidney cancer	8.69e-06	0.000221	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TSC2—kidney cancer	8.67e-06	0.00022	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTT1—kidney cancer	8.64e-06	0.00022	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ACHE—kidney cancer	8.64e-06	0.00022	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CRABP1—kidney cancer	8.63e-06	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—kidney cancer	8.6e-06	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—RAF1—kidney cancer	8.58e-06	0.000218	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—IL2—kidney cancer	8.47e-06	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—POMC—kidney cancer	8.45e-06	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTM1—kidney cancer	8.44e-06	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—RAF1—kidney cancer	8.44e-06	0.000215	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTP1—kidney cancer	8.44e-06	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—IL2—kidney cancer	8.33e-06	0.000212	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—MAPK1—kidney cancer	8.33e-06	0.000212	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KDR—kidney cancer	8.31e-06	0.000211	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL2—kidney cancer	8.23e-06	0.000209	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—SCARB1—kidney cancer	8.18e-06	0.000208	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS1—kidney cancer	8.1e-06	0.000206	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.07e-06	0.000205	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ITPR2—kidney cancer	8.03e-06	0.000204	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP1A1—kidney cancer	8.01e-06	0.000204	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ABCB1—kidney cancer	7.99e-06	0.000203	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTP1—kidney cancer	7.96e-06	0.000202	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PSMD7—kidney cancer	7.94e-06	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—KRAS—kidney cancer	7.86e-06	0.0002	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HIF1A—kidney cancer	7.84e-06	0.000199	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TSC2—kidney cancer	7.82e-06	0.000199	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTM1—kidney cancer	7.75e-06	0.000197	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL2—kidney cancer	7.69e-06	0.000195	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KIT—kidney cancer	7.65e-06	0.000195	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—APC—kidney cancer	7.65e-06	0.000195	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL2—kidney cancer	7.57e-06	0.000192	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ABCB1—kidney cancer	7.53e-06	0.000191	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—BCHE—kidney cancer	7.53e-06	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KDR—kidney cancer	7.5e-06	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF2—kidney cancer	7.48e-06	0.00019	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN2B—kidney cancer	7.44e-06	0.000189	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—SLC5A5—kidney cancer	7.43e-06	0.000189	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	7.4e-06	0.000188	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP1A1—kidney cancer	7.35e-06	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—POMC—kidney cancer	7.35e-06	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—MAPK3—kidney cancer	7.33e-06	0.000186	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HIF1A—kidney cancer	7.33e-06	0.000186	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTT1—kidney cancer	7.32e-06	0.000186	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ACHE—kidney cancer	7.32e-06	0.000186	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTM1—kidney cancer	7.31e-06	0.000186	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TSC2—kidney cancer	7.31e-06	0.000186	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—POMC—kidney cancer	7.29e-06	0.000185	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1R—kidney cancer	7.23e-06	0.000184	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PIK3CA—kidney cancer	7.22e-06	0.000184	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HIF1A—kidney cancer	7.21e-06	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—BRAF—kidney cancer	7.19e-06	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TSC2—kidney cancer	7.19e-06	0.000183	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—SLC2A1—kidney cancer	7.18e-06	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KDR—kidney cancer	7.01e-06	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—kidney cancer	6.99e-06	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—MAPK1—kidney cancer	6.98e-06	0.000177	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—RAF1—kidney cancer	6.97e-06	0.000177	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SCARB1—kidney cancer	6.93e-06	0.000176	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—APC—kidney cancer	6.91e-06	0.000176	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KIT—kidney cancer	6.91e-06	0.000176	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KDR—kidney cancer	6.9e-06	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—IL2—kidney cancer	6.88e-06	0.000175	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS1—kidney cancer	6.86e-06	0.000174	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PSMD7—kidney cancer	6.73e-06	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CA—kidney cancer	6.67e-06	0.000169	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—MAPK3—kidney cancer	6.62e-06	0.000168	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—KRAS—kidney cancer	6.59e-06	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—POMC—kidney cancer	6.58e-06	0.000167	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—BRAF—kidney cancer	6.5e-06	0.000165	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APC—kidney cancer	6.46e-06	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KIT—kidney cancer	6.46e-06	0.000164	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—BCHE—kidney cancer	6.38e-06	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KIT—kidney cancer	6.35e-06	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APC—kidney cancer	6.35e-06	0.000162	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SLC5A5—kidney cancer	6.3e-06	0.00016	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—MAPK1—kidney cancer	6.3e-06	0.00016	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL2—kidney cancer	6.25e-06	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—MAPK3—kidney cancer	6.18e-06	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—POMC—kidney cancer	6.14e-06	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—MAPK3—kidney cancer	6.08e-06	0.000155	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SLC2A1—kidney cancer	6.08e-06	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—BRAF—kidney cancer	6.07e-06	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CA—kidney cancer	6.05e-06	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—POMC—kidney cancer	6.05e-06	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CA—kidney cancer	6.02e-06	0.000153	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—RAF1—kidney cancer	6.01e-06	0.000153	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTP1—kidney cancer	5.99e-06	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—RELA—kidney cancer	5.98e-06	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—BRAF—kidney cancer	5.97e-06	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—POMC—kidney cancer	5.97e-06	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	5.95e-06	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—KRAS—kidney cancer	5.95e-06	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB2—kidney cancer	5.94e-06	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TSC2—kidney cancer	5.94e-06	0.000151	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.9e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—MAPK1—kidney cancer	5.88e-06	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MTOR—kidney cancer	5.87e-06	0.000149	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—kidney cancer	5.86e-06	0.000149	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—MAPK1—kidney cancer	5.79e-06	0.000147	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.69e-06	0.000145	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KDR—kidney cancer	5.69e-06	0.000145	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCB1—kidney cancer	5.67e-06	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—kidney cancer	5.62e-06	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—kidney cancer	5.56e-06	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—kidney cancer	5.53e-06	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1B—kidney cancer	5.5e-06	0.00014	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—kidney cancer	5.5e-06	0.00014	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—POMC—kidney cancer	5.48e-06	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—kidney cancer	5.47e-06	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—kidney cancer	5.46e-06	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RAF1—kidney cancer	5.42e-06	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RELA—kidney cancer	5.4e-06	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—kidney cancer	5.39e-06	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—kidney cancer	5.37e-06	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MTOR—kidney cancer	5.3e-06	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—kidney cancer	5.25e-06	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—kidney cancer	5.24e-06	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KIT—kidney cancer	5.24e-06	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—JUN—kidney cancer	5.24e-06	0.000133	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1A1—kidney cancer	5.22e-06	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—kidney cancer	5.2e-06	0.000132	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—POMC—kidney cancer	5.17e-06	0.000131	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.15e-06	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—kidney cancer	5.11e-06	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	5.1e-06	0.00013	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—kidney cancer	5.07e-06	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—kidney cancer	5.07e-06	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RAF1—kidney cancer	5.07e-06	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RELA—kidney cancer	5.04e-06	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	5.02e-06	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	5.02e-06	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	5.01e-06	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—POMC—kidney cancer	4.99e-06	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RAF1—kidney cancer	4.99e-06	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	4.97e-06	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RELA—kidney cancer	4.96e-06	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MTOR—kidney cancer	4.95e-06	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	4.93e-06	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—kidney cancer	4.93e-06	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MTOR—kidney cancer	4.87e-06	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—kidney cancer	4.86e-06	0.000124	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—kidney cancer	4.8e-06	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	4.78e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—kidney cancer	4.76e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—kidney cancer	4.74e-06	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JUN—kidney cancer	4.73e-06	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	4.69e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—kidney cancer	4.66e-06	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	4.64e-06	0.000118	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—kidney cancer	4.58e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—kidney cancer	4.58e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	4.57e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	4.57e-06	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—kidney cancer	4.54e-06	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	4.51e-06	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—kidney cancer	4.47e-06	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—kidney cancer	4.43e-06	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1A1—kidney cancer	4.42e-06	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JUN—kidney cancer	4.42e-06	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	4.39e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—kidney cancer	4.37e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—kidney cancer	4.36e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JUN—kidney cancer	4.35e-06	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK3—kidney cancer	4.33e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	4.32e-06	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—kidney cancer	4.27e-06	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—kidney cancer	4.21e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—kidney cancer	4.21e-06	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—kidney cancer	4.15e-06	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	4.15e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	4.13e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—kidney cancer	4.12e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK1—kidney cancer	4.12e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RAF1—kidney cancer	4.11e-06	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RELA—kidney cancer	4.1e-06	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	4.07e-06	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MTOR—kidney cancer	4.02e-06	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	3.91e-06	9.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—kidney cancer	3.89e-06	9.89e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—POMC—kidney cancer	3.89e-06	9.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	3.86e-06	9.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—kidney cancer	3.81e-06	9.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—kidney cancer	3.8e-06	9.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	3.8e-06	9.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	3.77e-06	9.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	3.72e-06	9.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—kidney cancer	3.69e-06	9.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	3.65e-06	9.28e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.63e-06	9.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—kidney cancer	3.61e-06	9.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—kidney cancer	3.6e-06	9.14e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—kidney cancer	3.59e-06	9.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	3.59e-06	9.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JUN—kidney cancer	3.59e-06	9.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—kidney cancer	3.58e-06	9.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	3.56e-06	9.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—kidney cancer	3.55e-06	9.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—kidney cancer	3.51e-06	8.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—kidney cancer	3.5e-06	8.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	3.47e-06	8.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—kidney cancer	3.47e-06	8.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—kidney cancer	3.46e-06	8.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	3.42e-06	8.69e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—POMC—kidney cancer	3.29e-06	8.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—kidney cancer	3.28e-06	8.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—kidney cancer	3.23e-06	8.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	3.23e-06	8.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	3.14e-06	7.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—kidney cancer	3.12e-06	7.94e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—kidney cancer	3.1e-06	7.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	3.02e-06	7.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	2.97e-06	7.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	2.97e-06	7.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—kidney cancer	2.93e-06	7.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—kidney cancer	2.92e-06	7.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—kidney cancer	2.89e-06	7.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—kidney cancer	2.87e-06	7.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	2.82e-06	7.17e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—kidney cancer	2.71e-06	6.88e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—kidney cancer	2.69e-06	6.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—kidney cancer	2.67e-06	6.78e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—kidney cancer	2.63e-06	6.68e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—kidney cancer	2.54e-06	6.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	2.45e-06	6.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—kidney cancer	2.37e-06	6.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—kidney cancer	2.29e-06	5.83e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.91e-06	4.85e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.62e-06	4.11e-05	CbGpPWpGaD
